Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 2/20 | 1.00 |
| ▸ | PGF | P49763 | 2/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 0.91 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.89 |
| ▸ | PRKCG | P05129 | 3/20 | 0.89 |
| ▸ | PRKCB | P05771 | 3/20 | 0.89 |
| ▸ | PRKCA | P17252 | 3/20 | 0.89 |
| ▸ | PRKCH | P24723 | 3/20 | 0.89 |
| ▸ | PRKCI | P41743 | 3/20 | 0.89 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.89 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.89 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.89 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.89 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.89 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | SNCA | P37840 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proanthocyanidin A2 SCHEMBL981583 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL14273881 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL13285132 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL18350173 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL15398842 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL981582 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL15394643 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL18214185 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL15399757 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 | |
| Proanthocyanidin A2 SCHEMBL29551197 | 1.00 | VEGFA (1.00) | VEGFAPGFPRKAA2FLT1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022023960-A1 | METHODS OF TREATING AND PREVENTING CORONAVIRUS INFECTION AND DISRUPTING CORONAVIRUS REPLICATION | FUNDACIÓN UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2022-02-03 | — | — | WO | claimed |
| US-20210146006-A1 | COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER | TRUELASTIN LABORATORIES, INC. | 2021-05-20 | — | — | US | claimed |
| US-10583218-B2 | Composite containing collagen and elastin as a dermal expander and tissue filler | HANCOCK JAFFE LABORATORIES AESTHETICS, INC. (US) | 2020-03-10 | — | — | US | claimed |
| CN-106265627-A | Method for treating inflammatory diseases and application of proanthocyanidin compound as medicine for treating inflammatory diseases | 香港浸会大学 | 2017-01-04 | — | — | CN | claimed |
| US-20160374985-A1 | Bioactivity proanthocyanidin compound isolated from Lasia spinosa (L.) Thwait | UNIV HONG KONG BAPTIST UNIV (HK) | 2016-12-29 | — | — | US | claimed |
| CN-103619414-A | Hair dyeing process employing at least one dihydroxyflavanol, a manganese or zinc salt, hydrogen peroxide, (bi)carbonate, an alkaline agent and a magnesium, molybdenum or calcium salt | OREAL | 2014-03-05 | — | — | CN | claimed |
| US-20120010146-A1 | COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER | HANCOCK JAFFE LABORATORIES, INC. (US) | 2012-01-12 | — | — | US | claimed |
| WO-2010053918-A1 | COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER | HANCOCK JAFFE LABORATORIES, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| EP-4079737-B1 | SYSTEM AND METHOD FOR SOLUTION PHASE GAP PEPTIDE SYNTHESIS | UNIV TEXAS TECH SYSTEM (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12344632-B2 | System and method for solution phase gap peptide synthesis | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250206710-A1 | COMPOSITIONS AND METHODS RELATED TO THE SIMULTANEOUS MANUFACTURE AND PURIFICATION OF FLAVOR AND FRAGRANCE MOLECULES | NATURAL EXTRACTION SYS LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250154118-A1 | Compositions and Methods Related to the Simultaneous Manufacture and Purification of Flavor and Fragrance Molecules | NATURAL EXTRACTION SYS LLC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-3891204-B1 | POLYCARBOXYLIC ACID COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES, ESPECIALLY HAIR | MOMENTIVE PERFORMANCE MAT INC (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-113164357-B | Use of polycarboxylic acid compounds for treating fibrous substrates based on amino acids, in particular hair | 迈图高新材料公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-101862270-A | Composition comprising ortho-diphenol, metal salt, hydrogen peroxide, (bi)carbonate | OREAL | 2010-10-20 | — | — | CN | disclosed |
| CN-101791269-A | Use contains the colouring method of the compositions of at least a neighbour-Benzodiazepines, a kind of slaine, hydrogen peroxide and carbonate or bicarbonate | OREAL | 2010-08-04 | — | — | CN | disclosed |
| CN-101785746-A | Use the colouring method that comprises wiping, drying or non-rinse step of neighbour-Benzodiazepines | OREAL | 2010-07-28 | — | — | CN | disclosed |
| WO-2010053918-A1 | COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER | HANCOCK JAFFE LABORATORIES, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20080090898-A1 | Boosting immunity | MARS, INCORPORATED (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070004652-A1 | Treatment of occlusive thrombosis | MARS, INCORPORATED (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344632-B2 | System and method for solution phase gap peptide synthesis | SBDS, NGLY1, GAP43 | VEGFA 1986/4885PGF 2658/4885PRKAA2 3346/4885 |
| US-20160374985-A1 | Bioactivity proanthocyanidin compound isolated from Lasia spinosa (L.) Thwait | MPO, MMP10, SERPINB1 | VEGFA 714/4885PGF 1385/4885PRKAA2 2353/4885 |
| US-20080090898-A1 | Boosting immunity | TLR7, TLR1, MYD88 | VEGFA 2121/4885PGF 907/4885PRKAA2 2755/4885 |
| US-20070004652-A1 | Treatment of occlusive thrombosis | PROC, F2, SERPINC1 | VEGFA 75/4885PGF 171/4885PRKAA2 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.